Taiho Oncology, Inc.
Aparna Dingari is an experienced professional in global regulatory affairs with a focus on Chemistry, Manufacturing, and Controls (CMC). Currently serving as Associate Director at Taiho Oncology, Inc. since October 2022, Aparna builds on prior experience as Sr. Manager at Genpact from December 2021 to September 2022. A significant tenure at SUN PHARMA from January 2010 to October 2021 included roles as Sr. Manager and Manager in the MSTG department, along with experience as a Sr. Scientist. Aparna holds a Master's Degree in Pharmaceutical Sciences from Temple University and a Master's Degree in Biology/Biological Sciences and Chemistry from Osmania University.
This person is not in any teams
Taiho Oncology, Inc.
2 followers
The mission of Taiho Oncology, Inc. is to improve the lives of patients with cancer, their families and their caregivers. The company specializes in the development of orally administered anti-cancer agents and markets these medicines for a range of tumor types in the U.S. Taiho Oncology’s growing pipeline of selectively targeted anti-cancer agents is led by a world-class clinical development organization. Taiho Oncology is a subsidiary of Taiho Pharmaceutical Co., Ltd. which is part of Otsuka Holdings Co., Ltd. Taiho Oncology is headquartered in Princeton, New Jersey and oversees its parent company’s European and Canadian operations, which are located in Zug, Switzerland and Oakville, Ontario, Canada. For more information, visit www.taihooncology.com